By the way, doctor: Is Avastin for macular degeneration a good choice?
Vascular endothelial growth factor (VEGF) is a naturally occurring signaling protein that stimulates the formation of blood vessels — a process called angiogenesis — in the eye and other parts of the body. Avastin — the generic name is bevacizumab — is one of the anti-VEGF, anti-angiogenesis drugs that have greatly improved the treatment of wet macular degeneration. By impeding the action of VEGF, these drugs block the formation of new blood vessels and may make them less likely to leak.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
